Volume 2.02 | Jan 21

Mammary Cell News 2.02, January 21, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe


Cell of Origin Identified for Common Type of Breast Cancer
Researchers propose a new model for breast cell differentiation that identifies two populations of progenitor cells, one of which appears to be the cell of origin for luminal-like breast cancer, the most common form of the disease. [Tufts University, Boston]



‘Chattering’ Receptors Drive Breast Cancer
Scientists have shown for the first time how preventing two receptors from communicating with each other can influence the activity of estrogen, the hormone that fuels the progression of breast cancer in many women. [Cancer Research United Kingdom, Cambridge]

Breakthrough Breast Cancer Therapy Reduces Mastectomies
A new treatment not only killed large breast cancer tumors, but reduced the need for mastectomies by almost 90 percent. [University of Oklahoma, Oklahoma City]




Monoacylglycerol Lipase Regulates a Fatty Acid Network that Promotes Cancer Pathogenesis
Researchers show that the enzyme monoacylglycerol lipase is highly expressed in aggressive human cancer cells and primary tumors, where it regulates a fatty acid network enriched in oncogenic signaling lipids that promotes migration, invasion, survival, and in vivo tumor growth. [Cell]

Cyclin D1 Kinase Activity Is Required for the Self-Renewal of Mammary Stem and Progenitor Cells that Are Targets of MMTV-ErbB2 Tumorigenesis
Using a kinase-deficient cyclin D1 mouse, researchers identified two functional mammary progenitor cell populations, one of which is the target of MMTV-ErbB2. [Cancer Cell]

Regulation of Breast Cancer Stem Cell Activity by Signaling through the Notch4 Receptor
The findings suggest that Notch4-targeted therapies will be more effective than targeting Notch1 in suppressing breast cancer recurrence, as it is initiated by breast cancer stem cells. [Cancer Res]

Heterogeneity of Gene Expression in Stromal Fibroblasts of Human Breast Carcinomas and Normal Breast
Carcinoma-associated fibroblasts (CAF) support and promote tumorigenesis, whereas normal mammary fibroblasts (NF) are thought to suppress tumor progression. Little is known about the difference in gene expression between CAF and NF or the patient-to-patient variability in gene expression. [Oncogene]

Cooperative Interaction Between Retinoic Acid Receptor-Alpha and Estrogen Receptor in Breast Cancer
Retinoic acid receptor-alpha is required for efficient estrogen receptor-alpha-mediated transcription and cell proliferation. [Genes Dev]

Glypican-3 Reexpression Regulates Apoptosis in Murine Adenocarcinoma Mammary Cells Modulating PI3K/Akt and p38MAPK Signaling Pathways
Glypican-3 inhibits the PI3K/Akt anti-apoptotic pathway while it stimulates the p38MAPK stress-activated pathway. [Breast Cancer Res Treat]


Phase II Trial of Primary Systemic Therapy with Doxorubicin and Docetaxel Followed by Surgery, Radiotherapy, and Adjuvant Chemotherapy with Cyclophosphamide, Methotrexate, and 5-Fluorouracil Based on Clinical and Pathologic Response in Patients with Stage IIB to III Breast Cancer : Long-Term Results from The University of Texas M. D. Anderson Cancer Center Study ID97-099
This study was performed to evaluate the outcomes of patients with locally advanced breast cancer who were treated with a multidisciplinary approach including primary systemic chemotherapy and noncross-resistant adjuvant chemotherapy. [Cancer]

A Phase 1B Dose Escalation Trial of Scutellaria barbata (BZL101) for Patients with Metastatic Breast Cancer
The study concluded that the oral administration of BZL101 was safe, well tolerated, and showed promising clinical evidence of anticancer activity in this heavily pretreated population of women with metastatic breast cancer. [Breast Cancer Res Treat]



Bionovo Announces Publication of Positive Results From the Phase 1B Clinical Trial of Bezielle (BZL101) for Metastatic Breast Cancer
The results demonstrate that Bezielle continues to be safe and well tolerated with clinical evidence of anticancer activity in a heavily pretreated population of women diagnosed with metastatic breast cancer. [Bionovo Inc. Press Release]

Medifocus, Inc. Announces Its Breast Cancer Treatment is Getting Nationwide Coverage after Positive Clinical Results Published in Annals of Surgical Oncology: Results Indicate Potentially Reducing the Need for Mastectomy
Medifocus, Inc. is pleased to announce that a review article summarizing clinical studies of the Company’s Microfocus APA 1000 Breast Cancer Thermotherapy System was published online. [Medifocus, Inc. Press Release]


Advisory Committees; Tentative Schedule of Meetings for 2010 [Food and Drug Administration, United States]

Proposed FDA Rulemaking on Informed Consent Requirements (NOT-OD-10-046) [National Institutes of Health, United States]

PHS 2010-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (PA-10-051) [National Institutes of Health, United States]

IACUC 101 and 201 PLUS Workshops: February 24-25, 2010 in Lafayette, LA (NOT-OD-10-044) [National Institutes of Health, United States]


27th Annual Miami Breast Cancer Conference
March 3-6, 2010
Miami, United States

7th European Breast Cancer Conference
March 24-27, 2010
Barcelona, Spain

ASBD’s 34th Annual Symposium
April 16-17, 2010,
New York City, Untied States

BIT’s 3rd Annual World Cancer Congress 2010 – Breast Cancer Conference
April 25-27, 2010
Shanghai, China

IMPAKT Breast Cancer Conference
May 6-8, 2010
Brussels, Belgium

Breast Cancer Research 2010 Conference
May 18, 2010
London, United Kingdom

ASCO Annual Meeting
June 4-8, 2010
Chicago, United States

Gordon Research Conference: Mammary Gland Biology
June 6-11, 2010
Lucca (Barga), Italy

12th Milan Breast Cancer Conference
June 16-18, 2010
Milan, Italy

The 21st Meeting of the European Association for Cancer Research
June 26-29, 2010
Oslo, Norway

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


Business Development Europe – Cell Therapy Products (PALL Corporation)

Research & Development Scientist – Pancreatic Cell Biology (STEMCELL Technologies)

Research & Development Scientist – Endothelial Cell Biology (STEMCELL Technologies)

Research & Development Scientist – Epithelial Cell Biology (STEMCELL Technologies)

Data Entry Assistant – Marketing (STEMCELL Technologies)

Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.
Visit here to post your career opportunities.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!


Learn more about Mammary Cell News: Archives  |  Events  |  Subscribe  |  Contact Us